Serra J, Pohl D, Azpiroz F, Chiarioni G, Ducrott P, Gourcerol G, et al
Semaglutide binds to and activates GLP-1 receptors in pancreatic beta cells, enhancing glucose-dependent insulin secretion while suppressing inappropriate glucagon release
Receptor agonist therapy offers targeted action, predictable dose responses, and potential reduction of adverse effects
Gut microbiota contribute to MASLD development through various mechanisms, including disruption of liver choline metabolism (necessary for VLDL synthesis and liver lipid export) (150), alterations in bile acid synthesis (151, 152), ethanol production (153), and increased lipopolysaccharides (LPS), which results in liver inflammation (154156)
Who Should Avoid GLP-1 During Breastfeeding and What Alternatives Exist Healthcare providers strongly discourage GLP-1 use in mothers who are actively breastfeeding or plan to breastfeed